Results 1 to 10 of about 9,892 (240)

Trajectories of Kidney Function in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan [PDF]

Medicina
Background and Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease, and the only approved pharmacological therapy shown to slow disease progression is tolvaptan.
Zofia Jankowska, Mariusz Niemczyk
doaj   +4 more sources

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis

Nefrología (English Edition), 2023
Background: The irreversible progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal disease (ESRD) is delayed by tolvaptan.
Xuanwei Li, Wenlai Li, Yue Li, Chuanjiang Dong, Ping Zhu   +4 more
doaj   +4 more sources

Severe tolvaptan-associated hyperglycemia: a case report [PDF]

Journal of Medical Case Reports
Background Tolvaptan-associated hyperglycemia has rarely been described in literature. Case presentation A 95-year-old East Asian (Chinese) male patient with hyponatremia started on tolvaptan treatment at a dosage of 15 mg per day.
Huihuan Sun, Ping Yang, Lijuan Chen, Ying Zhang, Shudong Liu, Wenxiu Sun   +5 more
doaj   +2 more sources

Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5 [PDF]

Kidney International Reports
Introduction: Improvement of estimated glomerular filtration rate (eGFR) slope has been established using tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Akinari Sekine, Junichi Hoshino, Toshio Mochizuki, Shinya Nakatani, Saori Nishio, Tatsuya Suwabe, Hiroki Hayashi, Hirayasu Kai, Koichi Seta, Fumihiko Hattanda, Sumi Hidaka, Kazushige Hanaoka, Mahiro Kurashige, Hiroshi Kataoka, Kiyotaka Uchiyama, Keiji Shimazu, Eiji Ishikawa, Yosuke Shimada, Haruna Kawano, Ken Tsuchiya, Shigeo Horie, Ichiei Narita, Yoshitaka Isaka, Satoru Muto   +23 more
doaj   +2 more sources

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF) [PDF]

ESC Heart Failure, 2020
Aims Hyponatremia is associated with poorer outcomes and diuretic response in patients hospitalized for heart failure. This study compared a tolvaptan‐based vs.
Tien M.H. Ng, Luanda P. Grazette, Michael W. Fong, Andrew J. Yoon, Mimi Lou, Allen Kuo, Rani Y. Upadhyay, Emily E. Han, Anilkumar Mehra, Uri Elkayam   +9 more
doaj   +2 more sources

Adding Tolvaptan in the Inpatient Treatment for Patients with Heart Failure and Hyponatremia: Budget Impact Analysis in Thailand [PDF]

ClinicoEconomics and Outcomes Research
Unchalee Permsuwan,1,2 Krit Leemasawat,3 Poukwan Arunmanakul1,2,4 1Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand; 2Center for Medical and Health Technology Assessment (CM-HTA), Department of ...
Permsuwan U, Leemasawat K, Arunmanakul P
doaj   +2 more sources

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use

PLoS ONE, 2022
Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction.
Hiroki Mizuno, Akinari Sekine, Tatsuya Suwabe, Daisuke Ikuma, Masayuki Yamanouchi, Eiko Hasegawa, Naoki Sawa, Yoshifumi Ubara, Junichi Hoshino   +8 more
doaj   +2 more sources

Long-Term Experience of Tolvaptan: Is Hepatotoxicity Still a Concern? [PDF]

Kidney360
Brown PA, Bubolic S, Laplante A, Jaeger T, Alam A.   +4 more
europepmc   +2 more sources

In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan

Journal of Pharmacological Sciences, 2022
Tolvaptan is an orally active vasopressin V2 receptor antagonist and used for the treatment of volume overload in some disease as an aquaretic. Tolvaptan sodium phosphate (OPC-61815) is a pro-drug of tolvaptan that was designed to improve water ...
Hiroyuki Fujiki, Masayuki Matsunaga, Masayuki Furukawa, Tatsuya Yamashita, Shigeki Nakamura, Toshiki Miyazaki, Hiroshi Mizuguchi, Yasuhiro Menjo, Takakuni Matsuda, Yoshihisa Yamada   +9 more
doaj   +1 more source

The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry

ESC Heart Failure, 2023
Aims The use of tolvaptan is increasing in clinical practice in Japan. However, the characteristics of patients who used tolvaptan and the timing of its use in patients with acute heart failure (AHF) are not fully elucidated.
Ryusuke Nishikawa, Takao Kato, Takeshi Morimoto, Hidenori Yaku, Yasutaka Inuzuka, Yodo Tamaki, Erika Yamamoto, Neiko Ozasa, Tomohisa Tada, Hiroki Sakamoto, Yuta Seko, Masayuki Shiba, Yusuke Yoshikawa, Yugo Yamashita, Takeshi Kitai, Ryoji Taniguchi, Moritake Iguchi, Kazuya Nagao, Takafumi Kawai, Akihiro Komasa, Yuichi Kawase, Takashi Morinaga, Mamoru Toyofuku, Yutaka Furukawa, Kenji Ando, Kazushige Kadota, Yukihito Sato, Koichiro Kuwahara, Takeshi Kimura, for the KCHF Study Investigators   +29 more
doaj   +1 more source